Flex Pharma

Flex Pharma is a biotechnology company that is developing treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The Company's lead drug product candidate, FLX-787, is currently in exploratory Phase 2 clinical trials in Australia in patients with multiple sclerosis, or MS, and amyotrophic lateral sclerosis, or ALS.It expect to initiate a Phase 2 clinical trial in the United States of FLX-787 in patients with motor neuron disease, primarily with ALS, and another Phase 2 clinical trial in patients with Charcot-Marie-Tooth disease, or CMT. In addition, Flex Pharma launched its consumer product, HOTSHOT, to prevent and treat exercise-associated muscle cramps, or EAMCs.

Company Growth (employees)
Type
Public
HQ
Boston, US
Founded
2014
Size (employees)
30 (est)-18%
Flex Pharma was founded in 2014 and is headquartered in Boston, US

Key People/Management at Flex Pharma

William McVicar

William McVicar

President and Chief Executive Officer

Flex Pharma Office Locations

Flex Pharma has an office in Boston
Boston, US (HQ)
800 Boylston Street

Flex Pharma Financials and Metrics

Flex Pharma Financials

Flex Pharma's revenue was reported to be $1 m in FY, 2016
USD

Revenue (Q2, 2017)

335.5 k

Net income (Q2, 2017)

(8.8 m)

EBIT (Q2, 2017)

(8.9 m)

Market capitalization (13-Nov-2017)

66.2 m

Cash (30-Jun-2017)

39.1 m
Flex Pharma's current market capitalization is $66.2 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

1 m

R&D expense

40 m4 m4 m

General and administrative expense

4 m4 m4 m

Operating expense total

44.1 m8 m8 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

112.7 k599.1 k242.5 k335.5 k

Cost of goods sold

110.9 k

Gross profit

1.8 k

Gross profit Margin, %

2%
USDFY, 2014FY, 2015FY, 2016

Cash

33.9 m66.7 m22.4 m

Accounts Receivable

12.2 k

Inventories

370.4 k908.6 k926 k

Current Assets

34.2 m92.2 m62.5 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

110.5 m106 m89.2 m54 m38.9 m27.8 m21.1 m39.1 m

Accounts Receivable

11.6 k21.8 k19.1 k34.7 k

Inventories

112.6 k274.3 k230.8 k414.3 k688.2 k

Current Assets

111.6 m106.8 m100.2 m86.5 m77.4 m69.1 m54.8 m49.1 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(8 m)(8 m)(8 m)

Depreciation and Amortization

12 k49.9 k277.2 k

Inventories

(370.4 k)(370.4 k)(370.4 k)

Accounts Payable

254.3 k254.3 k254.3 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(92.7 k)(7.1 m)(8.2 m)(9.6 m)(11.4 m)(10.6 m)(8.3 m)

Accounts Receivable

11.6 k21.8 k19.1 k

Inventories

112.6 k274.3 k230.8 k414.3 k

Accounts Payable

567.9 k812.3 k692.7 k1.5 m1.5 m1.3 m818.8 k
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

Flex Pharma Market Value History

Flex Pharma Revenue Breakdown

Flex Pharma's Web-traffic and Trends

Flex Pharma Online and Social Media Presence

Flex Pharma Company Life and Culture

You may also be interested in